GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » Short Percentage of Float

Resonance Health (ASX:RHT) Short Percentage of Float


View and export this data going back to 1987. Start your Free Trial

What is Resonance Health Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Resonance Health's Short Percentage of Float

For the Health Information Services subindustry, Resonance Health's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Health's Short Percentage of Float Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Resonance Health's Short Percentage of Float falls into.



Resonance Health Business Description

Traded in Other Exchanges
N/A
Address
141-143 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.

Resonance Health Headlines

No Headlines